TY - JOUR
T1 - Characteristics and outcomes of over 300,000 patients with COVID-19 and history of cancer in the United States and Spain
AU - Roel, Elena
AU - Pistillo, Andrea
AU - Recalde, Martina
AU - Sena, Anthony G.
AU - Fernández-Bertolín, Sergio
AU - Aragón, Maria
AU - Puente, Diana
AU - Ahmed, Waheed Ul Rahman
AU - Alghoul, Heba
AU - Alser, Osaid
AU - Alshammari, Thamir M.
AU - Areia, Carlos
AU - Blacketer, Clair
AU - Carter, William
AU - Casajust, Paula
AU - Culhane, Aedin C.
AU - Dawoud, Dalia
AU - DeFalco, Frank
AU - DuVall, Scott L.
AU - Falconer, Thomas
AU - Golozar, Asieh
AU - Gong, Mengchun
AU - Hester, Laura
AU - Hripcsak, George
AU - Tan, Eng Hooi
AU - Jeon, Hokyun
AU - Jonnagaddala, Jitendra
AU - Lai, Lana Y.H.
AU - Lynch, Kristine E.
AU - Matheny, Michael E.
AU - Morales, Daniel R.
AU - Natarajan, Karthik
AU - Nyberg, Fredrik
AU - Ostropolets, Anna
AU - Posada, Jose D.
AU - Prats-Uribe, Albert
AU - Reich, Christian G.
AU - Rivera, Donna R.
AU - Schilling, Lisa M.
AU - Soerjomataram, Isabelle
AU - Shah, Karishma
AU - Shah, Nigam H.
AU - Shen, Yang
AU - Spotniz, Matthew
AU - Subbian, Vignesh
AU - Suchard, Marc A.
AU - Trama, Annalisa
AU - Zhang, Lin
AU - Zhang, Ying
AU - Ryan, Patrick B.
AU - Prieto-Alhambra, Daniel
AU - Kostka, Kristin
AU - Duarte-Salles, Talita
N1 - Funding Information:
A.G. Sena reports employment with Janssen R&D and Johnson & Johnson stock ownership. C. Blacketer reports other support from Janssen Research & Development during the conduct of the study, as well as other support from Janssen Research & Development outside the submitted work. S.L. DuVall reports grants from Genomic
Funding Information:
Health, Inc., Gilead Sciences Inc., GlaxoSmithKline PLC, Innocrin Pharmaceuticals Inc., Janssen Pharmaceuticals, Inc., Kantar Health, Myriad Genetic Laboratories, Inc., Novartis International AG, and Parexel International Corporation outside the submitted work. A. Golozar reports other support from Regeneron Pharmaceuticals outside the submitted work. L. Hester reports other support from Janssen R&D, LLC outside the submitted work. G. Hripcsak reports grants from NIH during the conduct of the study, as well as grants from Janssen Research outside the submitted work. K. Natarajan reports grants from NIH during the conduct of the study. F. Nyberg reports other support from AstraZeneca outside the submitted work. J.D. Posada reports grants from National Library of Medicine during the conduct of the study. V. Subbian reports grants from National Science Foundation, State of Arizona, Arizona Board of Regents, Agency for Healthcare Research and Quality, and NIH outside the submitted work. M.A. Suchard reports grants from U.S. Department of Veterans Affairs during the conduct of the study, as well as grants from U.S. NIH and IQVIA and personal fees from Janssen Research and Development outside the submitted work. P.B. Ryan reports employment with Janssen Research and Development and ownership of Johnson & Johnson stock. D. Prieto-Alhambra reports grants and other support from Amgen; grants, nonfinancial support, and other support from UCB Bio-pharma; and grants from Les Laboratoires Servier outside the submitted work; in addition, Janssen, on behalf of IMI-funded EHDEN and EMIF consortiums, and Synapse Management Partners have supported training programs organized by DPA’s department and open for external participants. K. Kostka reports other support from IQVIA and grants from NIH outside the submitted work. No disclosures were reported by the other authors.
Publisher Copyright:
© 2021 The Authors; Published by the American Association for Cancer Research
PY - 2021/10
Y1 - 2021/10
N2 - Background: We described the demographics, cancer subtypes, comorbidities, and outcomes of patients with a history of cancer and coronavirus disease 2019 (COVID-19). Second, we compared patients hospitalized with COVID-19 to patients diagnosed with COVID-19 and patients hospitalized with influenza. Methods: We conducted a cohort study using eight routinely collected health care databases from Spain and the United States, standardized to the Observational Medical Outcome Partnership common data model. Three cohorts of patients with a history of cancer were included: (i) diagnosed with COVID-19, (ii) hospitalized with COVID-19, and (iii) hospitalized with influenza in 2017 to 2018. Patients were followed from index date to 30 days or death. We reported demographics, cancer subtypes, comorbidities, and 30-day outcomes. Results: We included 366,050 and 119,597 patients diagnosed and hospitalized with COVID-19, respectively. Prostate and breast cancers were the most frequent cancers (range: 5%–18% and 1%–14% in the diagnosed cohort, respectively). Hematologic malignancies were also frequent, with non-Hodgkin’s lymphoma being among the five most common cancer subtypes in the diagnosed cohort. Overall, patients were aged above 65 years and had multiple comorbidities. Occurrence of death ranged from 2% to 14% and from 6% to 26% in the diagnosed and hospitalized COVID-19 cohorts, respectively. Patients hospitalized with influenza (n ¼ 67,743) had a similar distribution of cancer subtypes, sex, age, and comorbidities but lower occurrence of adverse events. Conclusions: Patients with a history of cancer and COVID-19 had multiple comorbidities and a high occurrence of COVID-19-related events. Hematologic malignancies were frequent. Impact: This study provides epidemiologic characteristics that can inform clinical care and etiologic studies.
AB - Background: We described the demographics, cancer subtypes, comorbidities, and outcomes of patients with a history of cancer and coronavirus disease 2019 (COVID-19). Second, we compared patients hospitalized with COVID-19 to patients diagnosed with COVID-19 and patients hospitalized with influenza. Methods: We conducted a cohort study using eight routinely collected health care databases from Spain and the United States, standardized to the Observational Medical Outcome Partnership common data model. Three cohorts of patients with a history of cancer were included: (i) diagnosed with COVID-19, (ii) hospitalized with COVID-19, and (iii) hospitalized with influenza in 2017 to 2018. Patients were followed from index date to 30 days or death. We reported demographics, cancer subtypes, comorbidities, and 30-day outcomes. Results: We included 366,050 and 119,597 patients diagnosed and hospitalized with COVID-19, respectively. Prostate and breast cancers were the most frequent cancers (range: 5%–18% and 1%–14% in the diagnosed cohort, respectively). Hematologic malignancies were also frequent, with non-Hodgkin’s lymphoma being among the five most common cancer subtypes in the diagnosed cohort. Overall, patients were aged above 65 years and had multiple comorbidities. Occurrence of death ranged from 2% to 14% and from 6% to 26% in the diagnosed and hospitalized COVID-19 cohorts, respectively. Patients hospitalized with influenza (n ¼ 67,743) had a similar distribution of cancer subtypes, sex, age, and comorbidities but lower occurrence of adverse events. Conclusions: Patients with a history of cancer and COVID-19 had multiple comorbidities and a high occurrence of COVID-19-related events. Hematologic malignancies were frequent. Impact: This study provides epidemiologic characteristics that can inform clinical care and etiologic studies.
UR - http://www.scopus.com/inward/record.url?scp=85116992369&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85116992369&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-21-0266
DO - 10.1158/1055-9965.EPI-21-0266
M3 - Article
C2 - 34272262
AN - SCOPUS:85116992369
VL - 30
SP - 1884
EP - 1894
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
SN - 1055-9965
IS - 10
ER -